血清学及肿瘤标志物对早期胃癌诊断的研究进展
Research Progress of Serology and Tumor Markers in the Diagnosis of Early Gastric Cancer
DOI: 10.12677/ACM.2022.1281121, PDF,   
作者: 刘楠楠*, 袁东红：延安大学附属医院消化科，陕西 延安
关键词: 胃癌；胃蛋白酶原；胃泌素；生物标志物；Gastric Cancer； Pepsinogen； Gastrin； Biomarker
摘要: 胃癌是全球最常见的恶性疾病之一，也是癌症相关死亡的第四大原因，虽然早期胃癌的5年生存率可达90%以上，但由于早期诊断率低，大多数患者出现时已进入晚期，失去了治愈的机会。在我国胃癌的诊断主要依靠胃镜及活检，但诊断率低于10%，且其作为一种有创检查，患者依从性较差，难以开展大规模的筛查。目前，为了提高早期胃癌的诊治率，通过检测血中的幽门螺杆菌(HP)、胃蛋白酶原(PG)、胃泌素(GC)、CEA、CA199等指标对早期胃癌的筛查取得了一定的成果，本文将从血清学及生物标志物的最新进展做一综述，旨在提高居民早期胃癌的检出率，从而改善居民的生活水平。
Abstract: Gastric cancer is one of the most common malignant diseases in the world and the fourth lead-ing cause of cancer-related death. Although the 5-year survival rate of early gastric cancer can reach more than 90%, due to the low early diagnosis rate, most patients present at an advanced stage. In the late stage, the chance for cure is lost. The diagnosis of gastric cancer in my country mainly relies on gastroscope and biopsy, but the diagnosis rate is less than 10%, and as an in-vasive test, the patient compliance is poor, and it is difficult to carry out large-scale screening. At present, in order to improve the diagnosis and treatment rate of early gastric cancer, the screening of early gastric cancer by detecting Helicobacter pylori (HP), pepsinogen (PG), gastrin (GC), CEA, CA199 and other indicators in blood has achieved certain results. This article will re-view the latest progress in serology and biomarkers, aiming to improve the detection rate of early gastric cancer in residents, thereby improving the living standards of residents.
文章引用：刘楠楠, 袁东红. 血清学及肿瘤标志物对早期胃癌诊断的研究进展[J]. 临床医学进展, 2022, 12(8): 7784-7790. https://doi.org/10.12677/ACM.2022.1281121

参考文献

[1] 屠江锋, 潘文胜, 陈小君, 等. 胃癌早期筛查的研究进展[J]. 实用肿瘤杂志, 2016, 31(6): 560-564.
[2] 梁玉萍, 刘维花, 杨落落, 等. 早期胃癌的筛查[J]. 中华内科杂志, 2014, 53(4): 325-326.
[3] Ishaq, S. and Nunn, L. (2015) Helicobacter pylori and Gastric Cancer: A State of the Art Review. Gastroenterology and Hepatology from Bed to Bench, 8, S6-S14.
[4] Khatoon, J., Rai, R.P. and Prasad, K.N. (2016) Role of Helicobacter pylori in Gastric Cancer: Updates. World Journal of Gastrointestinal Oncology, 8, 147-158. [Google Scholar] [CrossRef] [PubMed]
[5] Chang, W.L., Yeh, Y.C. and Sheu, B.S. (2018) The Impacts of H. pylori Virulence Factors on the Development of Gastroduodenal Diseases. Journal of Biomedical Scifence, 25, 1-9. [Google Scholar] [CrossRef] [PubMed]
[6] Roesler, B.M., Rabelo-Gonçalves, E.M. and Zeitune, J.M. (2014) Virulence Factors of Helicobacter pylori: A Review. Clinical Medicine Insights. Gastroenterology, 7, 9-17. [Google Scholar] [CrossRef] 
[7] Baj, J., Brzozowska, K., Forma, A., Maani, A., Sitarz, E. and Portincasa, P. (2020) Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Tran-sition in Gastric Carcinogenesis. The International Journal of Molecular Sciences, 21, 2544. [Google Scholar] [CrossRef] [PubMed]
[8] Baj, J., Korona-Glowniak, I., Forma, A., Maani, A., Sitarz, E., Rahnama-Hezavah, M., Radzikowska, E. and Portincasa, P. (2020) Mechanisms of the Epithelial-Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer. Cells, 9, 1055. [Google Scholar] [CrossRef] [PubMed]
[9] Hatakeyama, M. (2017) Structure and Function of Helicobacter pylori CagA, 104 China Continuing Medical Education, Vol. 10, No. 33 the First-Identified Bacterial Protein In-volved in Human Cancer. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 93, 196-219. [Google Scholar] [CrossRef] [PubMed]
[10] Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N. and Schlemper, R.J. (2001) Helicobacter pylori Infection and the Development of Gastric Cancer. The New England Journal of Medicine, 345, 784-789. [Google Scholar] [CrossRef] 
[11] Zhang, L., Blot, W.J., You, W.C., et al. (1996) Helicobacter pylori Antibodies in Relation to Precancerous Gastric Lesions in a Highrisk Chinese Population. Cancer Epidemi-ology, Biomarkers & Prevention, 5, 627-630.
[12] 韩小磊, 何雁鸿, 马金丹, 等. 血清胃蛋白酶原在胃癌复发预测中的临床价值[J]. 胃肠病学和肝病学杂志, 2021, 30(12): 1339-1343.
[13] 杜梅英, 魏小斌, 钟文洲, 等. 胃泌素-17、胃蛋白酶原比值在早期胃癌筛查中应用价值分析[J]. 临床军医杂志, 2021, 49(7): 760-761, 764.
[14] 印睿, 葛建新, 黄晓丽, 等. 胃蛋白酶原、HLA-G诊断早期胃癌及癌前病变的临床意义[J]. 国际检验医学杂志, 2021, 42(24): 2977-2980.
[15] 朱春平, 赵建业, 申晓军, 等. 血清胃泌素-17联合胃蛋白酶原检测对胃癌诊断价值的多中心临床研究[J]. 中华消化内镜杂志, 2017, 34(1): 19-23.
[16] 黄喜顺, 邓立新, 丘耀辉, 等. 血清PG、G-17联合CA72-4和13C UBT在早期胃癌的诊断价值[J]. 重庆医学, 2017, 46(10): 1346-1348.
[17] 陈志娟, 卢彩侠, 李艳艳, 等. 血清胃功能三项联合癌胚抗原和癌抗原72-4在胃癌早期筛查中的价值[J]. 中国肿瘤临床与康复, 2022, 29(2): 218-221.
[18] 唐承璐, 朱庆曦, 韩菊平, 等. 胃蛋白酶原及幽门螺杆菌抗体检测在早期胃癌筛查中的价值[J]. 湖南师范大学学报(医学版), 2019, 16(3): 99-102.
[19] 朱昱冰, 葛少华, 张连海, 等. 肿瘤标志物在胃癌患者中的诊断及预后价值[J]. 中华胃肠外科杂志, 2012, 15(2): 161-164.
[20] 徐明星, 李曼, 彭波, 等. 肿瘤标志物联检在胃癌早期诊断临床应用研究[J]. 中国实验诊断学, 2014, 18(6): 899-902.
[21] 付生弟, 谢辉. 肿瘤标志物CEA、CA19-9、CA72-4及CA242在胃癌诊断及预后判断中的应用价值[J]. 标记免疫分析与临床, 2016, 23(4): 428-430+450.
[22] 陈海燕. CA724、CEA、CA242、CA199肿瘤标志物联合检验在胃癌中的诊断价值[J]. 中国医药导报, 2012, 9(31): 97-98.
[23] 田福满, 韩波. 检测CA199、CA125、CA153及CEA在肿瘤诊断中的意义[J]. 临床和实验医学杂志, 2010, 9(7): 483-485.
[24] Asao, T., Fukuda, T., Yazawa, S. and Nagamachi, Y. (1991) Carcinoembryonic Antigen Levels in Peritoneal Washings Can Predict Peritoneal Recurrence after Curative Resection of Gastric Cancer. Cancer, 68, 44-47. [Google Scholar] [CrossRef] 
[25] Zhang, Y.S., Xu, J., Luo, G.H., Wang, R.C., Zhu, J., Zhang, X.Y., Nilsson-Ehle, P. and Xu, N. (2006) Detection of Car-cinoembryonic Antigen mRNA in Peritoneal Washes from Gastric Cancer Patients and Its Clinical Significance. World Journal of Gastroenterology, 12, 1408-1411. [Google Scholar] [CrossRef] [PubMed]
[26] Ballehaninna, U.K. and Chamberlain, R.S. (2012) The Clinical Utility of Serum CA 19-9 in the Diagnosis, Prognosis and Management of Pancreatic Adenocarcinoma: An Evidence Based Appraisal. Journal of Gastrointestinal Oncology, 3, 105-119.
[27] Feng, F., Tian, Y., Xu, G., Liu, Z., Liu, S., Zheng, G., Guo, M., Lian, X., Fan, D. and Zhang, H. (2017) Diagnostic and Prognostic Value of CEA, CA19-9, AFP and CA125 for Early Gastric Cancer. BMC Cancer, 17, Article No. 737. [Google Scholar] [CrossRef] [PubMed]
[28] Kochi, M., Fujii, M., Kanamori, N., Kaiga, T., Kawakami, T., Aizaki, K., Kasahara, M., Mochizuki, F., Kasakura, Y. and Yamagata, M. (2000) Evaluation of Serum CEA and CA19-9 Levels as Prognostic Factors in Patients with Gastric Cancer. Gastric Cancer, 3, 177-186. [Google Scholar] [CrossRef] 
[29] Sisik, A., Kaya, M., Bas, G., Basak, F. and Alimoglu, O. (2013) CEA and CA 19-9 Are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients. Asian Pacific Journal of Cancer Prevention, 14, 4289-4294. [Google Scholar] [CrossRef] 
[30] Zhou, Y.-C., Zhao, H.-J. and Shen, L.-Z. (2015) Pre-operative Serum CEA and CA19-9 in Gastric Cancer—A Single Tertiary Hospital Study of 1,075 Cases. Asian Pacific Journal of Cancer Prevention, 16, 2685-2691. [Google Scholar] [CrossRef] 
[31] Chen, C., Chen, Q., Zhao, Q., Liu, M. and Guo, J. (2017) Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer. Annals of Clinical and Laboratory Science, 47, 260-263.
[32] Sawayama, H., Iwatsuki, M., Kuroda, D., Toihata, T., Uchihara, T., Koga, Y., Yagi, T., Kiyozumi, Y., Eto, T., Hiyoshi, Y., et al. (2018) The Association of the Lymph Node Ratio and Serum Carbohydrate Antigen 19-9 with Early Recurrence after Curative Gastrectomy for Gastric Cancer. Surgery Today, 48, 994-1003. [Google Scholar] [CrossRef] [PubMed]
[33] Hasbahceci, M., Malya, F., Kunduz, E., Guler, M., Unver, N. and Akcakaya, A. (2018) Use of Serum and Peritoneal CEA and CA19-9 in Prediction of Peritoneal Dissemination and Survival of Gastric Adenocarcinoma Patients: Are They Prognostic Factors? Annals of the Royal College of Surgeons of England, 100, 257-266. [Google Scholar] [CrossRef] [PubMed]
[34] Sun, Z. and Zhang, N.-W. (2014) Clinical Evaluation of CEA, CA19-9, CA72-4 and CA125 in Gastric Cancer Patients with Neoadjuvant Chemotherapy. World Journal of Sur-gical Oncology, 12, 397. [Google Scholar] [CrossRef] [PubMed]
[35] Derks, S., Liao, X., Chiaravalli, A.M., et al. (2016) Abundant PD-L1 Expression in Epstein-Barr Virus-Infected Gastric Cancers. Oncotarget, 7, 32925- 32932. [Google Scholar] [CrossRef] [PubMed]
[36] Fukayama, M., Hayashi, Y., Iwasaki, Y., Chong, J., Ooba, T., Takizawa, T., Koike, M., Mizutani, S., Miyaki, M. and Hirai, K. (1994) Epstein-Barr Virus-Associated Gastric Carcinoma and Epstein-Barr Virus Infection of the Stomach. Laboratory Investigation, 71, 73-81.
[37] Camargo, M.C., Murphy, G., Koriyama, C., Pfeiffer, R.M., Kim, W.H., Herrera-Goepfert, R., Corvalán, A.H., Carrascal, E., Abdirad, A., Anwar, M., et al. (2011) Determinants of Epstein-Barr Virus-Positive Gastric Cancer: An International Pooled Analysis. British Journal of Cancer, 105, 38-43. [Google Scholar] [CrossRef] [PubMed]
[38] Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemo-therapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697. [Google Scholar] [CrossRef] 
[39] Van Cutsem, E., Bang, Y., et al. (2015) HER2 Screening Data from ToGA: Targeting HER2 in Gastric and Gastroesophageal Junction Cancer. Gastric Cancer, 18, 476-484. [Google Scholar] [CrossRef] [PubMed]
[40] Isgrò, M.A., Bottoni, P. and Scatena, R. (2015) Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Advances in Experimental Medicine and Biology, 867, 125-143. [Google Scholar] [CrossRef] [PubMed]
[41] Luo, H., et al. (2020) Clinical Significance of Serum Neuron-Specific Enolase in Gastric Adenocarcinoma. Medicine, 99, e19829. [Google Scholar] [CrossRef] 
[42] Wang, P., Piao, Y., Zhang, X., et al. (2013) The Con-centration of CYFRA 21-1, NSE and CEA in Cerebro-Spinal Fluid Can Be Useful Indicators for Diagnosis of Meningeal Carcinomatosis of Lung Cancer. Cancer Biomarkers, 13, 123-130. [Google Scholar] [CrossRef] 

为你推荐